


Changing diagnostic paradigms for microbiology
(AAM report 2016)



Point of care testing

Is it obvious?

Professor Pierrette Melin
National Reference Centre for *Streptococcus agalactiae*
Clinical Microbiology, University Hospital of Liege,
University of Liege, Belgium

LIÈGE université CHU de Liège

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 1

Changing diagnostic paradigms for microbiology
(AAM report 2016)

Point of care testing

Is it obvious?

- Clinically ?
- Technically ?
- Regulatory ?
- INAMI ?

LIÈGE université CHU de Liège

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 2

Outline

- Definitions & Background
- Types of POC tests
- Implementation
- Oversight of Near-Patient and Point-of-Care testing
- Evaluation
- Take home messages

LIÈGE université CHU de Liège

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 3

Definitions

- **POC** (Point of care)
 - At the time and location at which patient services are delivered
- **POCT** (Point-of-care testing) or **NPT**, Near-patient testing
 - **Medical testing and diagnosis carried out at, or close to, the site of patient care**
 - For **in-patients**, at bedside, in a regular exam room or in critical care facility (ED, ICU, etc.)
 - For **outpatients**, at home, at a local pharmacy, at local clinic's examination room, at physician's office, at nursing home or age-care centre
 - **Performed by specially trained healthcare professionals but not laboratory personnel.**
 - **Usually short TAT** (few minutes → 1 or 2 hours)
 - Rapid actionable results to improve outcome and reduce cost of care

LIÈGE université CHU de Liège

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 4

XXIst century, Medical evolutionary background
Factors impacting on development and daily practice of microbiology

- **Evolution of lab landscape**
 - **Centralization of core laboratories**
 - Serving more decentralized patients in network affiliated with a hospital
- **Medical environment**
 - Increasing emphasis on **evidence-based medicine** and adherence to **guidelines**
- **Evolution of technological background**
 - Exponential progress: molecular biology and robots
 - New platforms from "sample-in / result-out"
 - Continuation of advance to accelerate in the near future
- **Economic environment**
 - Cost-effective use of available resources
 - Reimbursement system, regulation
- **Quality assurance, traceability, LIS**
- **Global increase of antimicrobial resistance**

ISO

LIÈGE université CHU de Liège

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 5







What the clinician seek from the clinical microbiology laboratory

Three basic truths

- Is my patient infected ?
- If so, with what ?
- If so, what will treat it ?

LIÈGE université CHU de Liège

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 6



Rapid & accurate identification of a pathogen

Prime importance for effective provision of care to patients with infectious disease

The faster you identify pathogens, the quicker you can react to it,

- Supporting rapid initiation or cessation of atb treatment
- Implementing targeted treatment according to rational use of antibiotics when needed
- Preventive measures and control of infections
- Enhancing surveillance of pathogens and infectious diseases

Benefits are also for
The community, hospital and control measures

Sciensano 05.2019 / POCT / PM / CHUip-Ulg 13

POCT: types of tests

Shifting from antigen-based testing to nucleic acid amplification-based testing, including multiplex syndromic panels

1. Antigen, antibody tests

- Mainly lateral-flow immunochromatographic membrane-based assays (LFIA)
- Lower Sensitivity and specificity than NAAT
- Influenza A&B, Group A Streptococcus, infectious mononucleosis, Respiratory syncytial virus, HIV, *Treponema pallidum*, *Streptococcus pneumoniae*, *Legionella pneumophila* serogroup1, etc.

Sciensano 05.2019 / POCT / PM / CHUip-Ulg 14

POCT: types of tests

2. Nucleic Acid Amplification tests (NAAT)

- Detect DNA or RNA sequences specific to a particular target (present in a specific pathogen or antimicrobial resistance determinant)
 - FLU A/B; RSV, MRSA, CT/NG, C.difficile, Norovirus, GAS, GBS, Trichomonas, TB/Rif, etc.
- Different amplification methods
- Costly and need of specialized equipment
- Increased sensitivity, but limitations (contamination → F+; mutation → F-)

Sciensano 05.2019 / POCT / PM / CHUip-Ulg 15

POCT: types of tests

NAAT considerations

Diagnostic of Tuberculosis

- Challenge for low resources countries
- Improvement of diagnostic of TB, particularly in developing nations with high prevalence and often associated to HIV.
- NAAT to replace direct microscopy (sensitivity 50-60%) (+/- culture, suboptimal, too long)
- High sensitivity of NAAT
 - 98% of smear positive and 75% of smear negative patients
 - Results delivered within 2 hours → initiation of treatment the same day of healthcare visit !!
- Rapid, sensitive and specific :
 - Potential to replace microscopy
- Ability to identify rifampicin-resistant TB
- Minimum technical training required to run the test

Sciensano 05.2019 / POCT / PM / CHUip-Ulg 16

Time to result, 1 hour 45 minutes

Sciensano 05.2019 / POCT / PM / CHUip-Ulg 17

Desirable features of POC devices or on-field assay


- Quick reliable response
- Short Turn Around Time (TAT) < 1 hour ?
- Accuracy: high sensitivity, specificity, negative and positive predictive values
- As simple as possible, compliance with basic rules of GLP
- Ease of use: to perform and to interpret (clear-cut result) by unskilled minimally trained people
 - Low rate of invalid / error results
- Workflow; very limited hands-on-time
- Limited training
- Long shelf-life, minimized waste
- Availability 24h/7d
- Cost-effective
- Internal QC / embedded process control / control for presence of specimen on board
- Fully automated and robust test & platform
- Traceability, connectivity to electronic medical files
- Multiplexing capacity
- Small footprint, low noise level

Sciensano 05.2019 / POCT / PM / CHUip-Ulg 18

Why do we need better rapid POCT ?

In many cases a clinical presentation may be caused by a number of possible pathogens

- **Syndromic diseases**
 - Characterized by the abnormal presence, simultaneously, of a group of signs and symptoms



CNS infections Respiratory tract infections Gastro-enteritis Bloodstream infections

Sciensano 05.2019 / POCT / PM / CHUUp-ULg 19

Why do we need better rapid POCT ?

- **Syndromic diseases**
 - Characterized by the abnormal presence, simultaneously, of a group of signs and symptoms



CNS infections Gastro-enteritis Bloodstream infections

Bacteria, fungi, viruses, parasites

Sciensano 05.2019 / POCT / PM / CHUUp-ULg 20

Microbiological diagnostic approaches Transition

- **From conventional (aetiological) approach**
 - « Is a specific pathogen present in the specimen? »
 - Step by step, on demand (primarily directed to typical bacteria)
 - Varied individual methods
 - TAT : minutes to days or even weeks
- **To syndrome-based approach**
 - « Which pathogen is causing this syndrome? »

Sciensano 05.2019 / POCT / PM / CHUUp-ULg 21

Microbiological diagnostic approaches, transition

- **From conventional (aetiological) approach**
 - « Is a specific pathogen present in the specimen? »
 - Step by step, on demand (primarily directed to typical bacteria)
 - Varied individual methods
 - TAT : minutes to days or even weeks
- **To syndrome-based approach**
 - « Which pathogen is causing this syndrome? »
 - **Broad panel diagnostic method** (Including atypical agents, viruses, fungi, parasites)
 - **All inclusive testing system** « Sample-in / result-out »
 - TAT : 1-2 hour(s)

Sciensano 05.2019 / POCT / PM / CHUUp-ULg 22

Point-of-care-test platforms for early diagnosis of infection (FDA cleared- CE approved)

To provide an integrated, holistic solution addressing technological challenges

- **For rapid increased detection of bacteria, mycobacteria, fungi, viruses, host markers and resistance to antimicrobial drugs**
 - To enhance clinical decision-making
 - To improve quality of care and clinical outcomes
 - To improve targeted therapy and reduce overuse
- Specific probes (pathogens, R markers, virulence markers)
- From native patient's samples (limited volume)
- Novel methods of sample preparation
- Novel molecular solutions
- Ultra-high sensitive detection methods

Results availability
in less than 2 hours for IN/OUT patients

Sciensano 05.2019 / POCT / PM / CHUUp-ULg 23

Point-of-care-test platforms for early diagnosis of infection (FDA cleared- CE approved)

To provide an integrated, holistic solution addressing technological challenges

- **For rapid increased detection of bacteria, mycobacteria, fungi, viruses, host markers and resistance to antimicrobial drugs**
 - To enhance clinical decision-making
 - To improve quality of care and clinical outcomes
 - To improve targeted therapy and reduce overuse
- Specific probes (pathogens, R markers, virulence markers)
- From native patient's samples (limited volume)
- Novel methods of sample preparation
- Novel molecular solutions
- Ultra-high sensitive detection methods

Results availability
in less than 2 hours for IN/OUT patients

Huge challenges and synergies: Biotechnologies, microtechnologies and clinical practice

Sciensano 05.2019 / POCT / PM / CHUUp-ULg 24

All-inclusive systems for multiplex syndromic approach


(sample to answer multiplex molecular diagnostics)

- Systems covering all steps from sample preparation to results
- All reagents freeze-dried in one pouch
- Internal controls for each step!
- Closed system for preventing cross contamination
- Advanced software to run the system, results automatically analyzed and reported in a simple, easy to read format
- Multiplexed testing: for a large number of targets (> 20) per sample
 - Comprehensive Mx panels
- Results available in 1-2 hours following sample injection
- Testing easy to perform with minimal training (24h/7d)
- Bi-directional LIS interface


Sciensano 05.2019 / POCT / PM / CHULg-ULg 25

Among the choice of platforms and assays

BioFire FilmArray System, bioMérieux



ePlex System*, GenMark



- < 2 min of hands-on time
- Sample to result in +/- 60 minutes
- Bi-directional LIS interface
- Scalable system
- Random and continuous access
- In/out the laboratory
- Interpretation of positive results ?

- Meningitis / Encephalitis Panel
- Respiratory Pathogen Panel
- Blood Culture Id Panel
- Gastro-intestinal Panel

Concerns about indiscriminate deployment of syndromic panels when a nuanced approach is needed.

Sciensano 05.2019 / POCT / PM / CHULg-ULg 26

Implementation of POCT

- Goal**
 - to collect the specimen and obtain accurate results in a very short period of time at or near the location of the patient.
- Advantages**
 - to bring the test conveniently and immediately to the patient.
 - Including a variety of remote locations, meeting diverse medical needs.
 - To increase the likelihood of short TAT to get results quicker
 - To enable clinicians to support the timely diagnosis, triage, monitoring and treatment of patients if needed.
 - A lean process, less steps; redesigning workflow
- Caveats**
 - Many limitations if analysis procedures are not adhered to.
 - Essential that POCT is undertaken correctly to ensure accurate and reliable results and interpretation.
 - Are other results needed from non-POCT to manage patient?

Sciensano 05.2019 / POCT / PM / CHULg-ULg 27

Implementation of POCT

- Goal**
 - to collect the specimen and obtain accurate results in a very short period of time at or near the location of the patient.
- Advantages**
 - to bring the test conveniently and immediately to the patient.
 - Including a variety of remote locations, meeting diverse medical needs.
 - To increase the likelihood of short TAT to get results quicker
 - To enable clinicians to support the timely diagnosis, triage, monitoring and treatment of patients if needed.
 - A lean process, less steps; redesigning workflow
- Caveats**
 - Many limitations if analysis procedures are not adhered to.
 - Essential that POCT is undertaken correctly to ensure accurate and reliable results and interpretation.
 - Are other results needed from non-POCT to manage patient?

When over utilized or incorrectly performed, POCT presents a significant patient risk and potential for increased healthcare costs.

An incorrect test result can result in the wrong treatment and potentially life threatening consequences


Sciensano 05.2019 / POCT / PM / CHULg-ULg 28

International standards & quality assessment

- International standard for POCT : ISO 22870**
 - Point-of-care testing – requirements for quality and competence.
 - Specific requirements applicable to POCT
 - To be used in conjunction with ISO 15189, Medical laboratories – particular requirements for quality and competence.
 - The requirements of ISO 22870 "apply when POCT is carried out in a hospital, a clinic, or healthcare organisation providing ambulatory care"
- Internal Quality Control**
- External Quality Assessment**
 - Critical component in assuring the quality of results

Sciensano 05.2019 / POCT / PM / CHULg-ULg 29

Although POCT provides rapid results and the opportunity for faster medical decisions, the risk of errors with POCT often raises concern over the reliability of test results.



- Management / Oversight**
 - Infrastructure
 - Lab must be involved
 - Testing performed by non laboratory personnel
 - Need knowledge of specimen handling, QC, QA, etc.
- Analytical quality**
 - Reliability on results
 - Variations in test results from multiple testing platforms
- Regulatory**
 - Waived vs non-waived
- Training and competency assessments**
 - Need to track for all operators
 - Differing requirements between regulatory agencies and for waived or non waived tests
- Data management & connectivity**
 - Need to capture results electronically (to reduce errors, incorporate data)
 - Varying connectivity capabilities of POC devices
- Costs & billing**

Sciensano 05.2019 / POCT / PM / CHULg-ULg 30

Testing performed by Non-laboratory personnel

- **Nurses, medical assistants**
 - Minimal laboratory knowledge
 - **Focused on patient care**
 - Pressure of fast-paced environment
 - Unfamiliar to importance of proper calibration, instrument maintenance and QC !
 - Risk of mis-use, incorrect performance and mis-interpretation

**Why should they handle POCT ?
Isn't it the laboratory role !**

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 31

The Lab's Responsibility in POCT

- **To be part of decision for implementation of a POCT**
- **Responsible for training**
- **Organizer and oversight of QA**
- **To provide guidelines for proper ordering, for interpretation**
- **To conduct solid, high quality validation studies**
 - To balance benefits and harms
 - To evaluate impacts on patient care
 - To evaluate benefits for society as
 - Reduction of transmission of pathogens
 - More appropriate use of antibiotics
 - In one defined setting at a time

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 32


POCT Policy

Aims,

- **To ensure that**
 - POCT is used in a safe and effective way in accordance with best practice.
 - Results used for patient care are as near as possible in quality to those issued by accredited hospital laboratory

See Leeds Teaching Hospitals NHS Trust (LTH) website, policy applying to all employees.

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 33



Guidelines for prevention of GBS perinatal diseases
Efficacy, concerns & drawbacks
Room for improvement

POCT FOR GBS, ISN'T IT CLINICALLY OBVIOUS ?

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 34

Concerns about preventive strategies & IAP

	Risk-based approach	Antenatal screening-based approach
No IAP when needed	<ul style="list-style-type: none"> ▪ A lot of missed opportunities <ul style="list-style-type: none"> ▪ Lack of adhesion ▪ Incomplete assessment of risks ▪ Up to 65% of cases not associated to RF 	<ul style="list-style-type: none"> ▪ Some missed opportunities <ul style="list-style-type: none"> ▪ Results not available ▪ False Negative screening <ul style="list-style-type: none"> ▪ Change of GBS status <ul style="list-style-type: none"> ▪ Colonization dynamics ▪ Lack of viability <ul style="list-style-type: none"> ▪ Transport conditions, antibiotherapy, personal hygiene ▪ Poor sensitivity of culture
Unnecessary IAP	<ul style="list-style-type: none"> ▪ Half up to 80% of women with RF are not GBS colonized (except intrapartum fever) 	<ul style="list-style-type: none"> ▪ False Positive screening <ul style="list-style-type: none"> ▪ Change of GBS status ▪ Colonization dynamics <p style="text-align: center;">Up to 30% of antenatal positive</p>

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 35

Intrapartum screening Expected advantages & drawback

- Inclusion of women without antenatal screening / care
- Identification of women with change of GBS status after 35-37 wks gestation
- Increased accuracy of vaginal GBS colonization status at time of labor & delivery
- No antimicrobial susceptibility results
(→ in case of penicillin allergy, antenatal screening)

IAP addressed to right target

- Reduction of inappropriate / unnecessary IAP
- Broader coverage of « at GBS risk women »

Improvement of prevention

Sciensano 05.2019 / POCT / PM / CHU-Lg-ULg 36

MMWR
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr

Recommendations and Reports November 13, 2010 / Vol. 59 / No. 45-46

Prevention of Perinatal Group B Streptococcal Disease
Revised Guidelines from CDC, 2010

- In settings in which NAAT for GBS is available, obstetric providers can choose to perform intrapartum testing of vaginal-rectal samples from women with unknown GBS colonization status and no intrapartum risk factors (temperature of $\geq 100.4^{\circ}\text{F}$ [$\geq 38.0^{\circ}\text{C}$] or rupture of amniotic membranes ≥ 18 hours) at the time of testing and who are delivering at term (CII). If an intrapartum risk factor subsequently develops, antibiotic prophylaxis should be administered regardless of the intrapartum testing results (AIII).
- Women with positive intrapartum NAAT results for GBS should receive antibiotic prophylaxis (AII). NAAT testing is optional and might not be available in all settings.

Sciensano 05.2019 / POCT / PM / CHU-Lg-Ulg 37

MMWR
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr

Recommendations and Reports November 13, 2010 / Vol. 59 / No. 45-46

Prevention of Perinatal Group B Streptococcal Disease
Revised Guidelines from CDC, 2010

THE JOURNAL OF
MATERNAL-FETAL
& NEONATAL
MEDICINE

http://informahealthcare.com/jmf
ISSN: 1476-7058 (print), 1476-4954 (electronic)
J Matern Fetal Neonatal Med, Early Online: 1-17
© 2014 Informa UK Ltd. DOI: 10.1080/14767058.2014.938004

informa
healthcare

GUIDELINES

Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference

When adequate tests available !

G. C. Di Renzo³, P. Melin², A. Berardi¹, M. Blennow⁴, X. Carbonell-Estrany⁵, G. P. Donzelli⁶, S. Hakansson⁷, M. Hod⁸, R. Hughes⁹, M. Kurtzer¹⁰, C. Poyart¹¹, E. Shinwell¹², B. Stray-Pedersen¹³, M. Wielgos¹⁴, and N. El Helali¹⁵

Sciensano 05.2019 / POCT / PM / CHU-Lg-Ulg 38

Old or new tools to detect GBS ?
Response to a 30 year "dream" but also an obvious need.

**POCT FOR GBS,
IS IT TECHNICALLY OBVIOUS ?**

Sciensano 05.2019 / POCT / PM / CHU-Lg-Ulg 39

Xpert® GBS results (Liege, 2014)
Intrapartum (IP) culture as gold standard

Pre-study	Study	Post-study	Following period
08.04	26.05		10.09
			Following period
			14
Number tested / Number GBS Positive Culture			!!
Sensitivity Excluding enrichment			!!
Specificity			
PPV	93.3%	87.5%	
NPV	91.7%	98.5%	87.2%
Error + Invalid results		3% - 11%	

Gentle rolling of the swab in order to eliminate excess of mucus

Sciensano 05.2019 / POCT / PM / CHU-Lg-Ulg 40

Xpert® GBS POCT in the delivery room

- High specificity but varying sensitivities !
- Some invalid or error results
 - Time, cost to retest ???
- Some expected improvements to secure the result AND the patient management (specimen control)
- Mucus interference
- Higher Ct when test perform immediately after collection: better results a few hours later

Commutability from lab to POC:
Not always an unconditional success story !
→ Clinical validation of GBS POCT: crucial to be performed (1) on site, (2) by midwives and (3) on fresh specimens

Sciensano 05.2019 / POCT / PM / CHU-Lg-Ulg 41

POCT - CONCLUSION
Take home messages

- Increasingly needed and implemented in new settings
- Clinical microbiology laboratory expertise needed
 - To oversight quality assurance, competency, proficiency testing
- Integration of POC results in LIS, electronic medical file
- Rapidly evolving
 - Automation, simplification, and miniaturization
 - To associate with the detection of biomarkers
- Impact on patient outcomes, healthcare delivery models, public health, healthcare costs
 - Still not clear, to evaluate
- Need for guidelines
 - To place orders, to perform, to interpret correctly, to implement
- Need for new reimbursement rules
 - Moving from lowest cost per test to total cost of care; focus on medical outcome

Sciensano 05.2019 / POCT / PM / CHU-Lg-Ulg 42

Recommendations of AAM, 2016

Implementation	Oversight	Evaluation
<ul style="list-style-type: none"> • Redesign clinic workflows to incorporate near-patient and point-of-care (POC) testing. • Promote proper interpretation of tests to avoid adverse outcomes. • Provide resources, such as training videos, to support appropriate self-collection of patient specimens. • Ensure that public health surveillance of infectious diseases is maintained with POC testing. • Link near-patient and POC test results to the patient's electronic medical record (EMR). 	<ul style="list-style-type: none"> • Maintain clinical microbiology laboratory expertise and oversight of infectious disease tests. • Utilize competent personnel to oversee ordering, testing, and interpretation. • Educate providers and patients on different types of tests. 	<ul style="list-style-type: none"> • Conduct clinical outcomes and cost-effectiveness studies for near-patient and POC tests. • Evaluate near-patient and POC tests periodically and undertake regulatory action or reclassification for tests that do not meet performance standards.

References

- **Changing Diagnostic Paradigms for Microbiology**, Report on an American Academy of Microbiology Colloquium held in Washington, DC, from 17 to 18 October 2016. Virginia Dolen, *Rapporteur*
- Messacar K, Parker SK, Todd JK, Dominguez SR. 2017. **Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship**. J Clin Microbiol 55:715–723. <https://doi.org/10.1128/JCM.02264-16>.
- Drancourt M, Michel-Lepage A, Boyer S, Raoult D. 2016. **The point-of-care laboratory in clinical microbiology**. Clin Microbiol Rev 29:429 – 447. doi:10.1128/CMR.00090-15.

... one does not have to wait for the ultimate technical solutions to begin saving lives.
Urdea et al, Requirements for high impact diagnostics in the developing world. Nature, 2006

**Time is of the essence in an emergency setting,
 and can be the difference between life and death.**

Thank you !

